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Gastric cancers express enhanced levels of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs). Single-nucleotide
polymorphisms (SNPs) in MMP and TIMP genes may be associated with disease susceptibility and might also affect their antigen
expression. We studied the genotype distribution and allele frequencies of SNPs of MMP-2, -7, -8 and -9 and TIMP-1 and -2 in gastric
cancer patients in relation to tumour progression, patient survival and tissue antigen expression. The genotype distribution and allele
frequencies were similar in gastric cancer patients and controls, except for MMP-7 181A4G. In addition, the genotype distribution
of MMP-7 181A4G was associated with Helicobacter pylori status (w
2 7.8, P¼0.005) and tumour-related survival of the patients.
Single-nucleotide polymorphism TIMP-2303C4T correlated significantly with the WHO classification (w
2 5.9, P¼0.03) and also
strongly with tumour-related survival (log rank 11.74, P¼0.0006). Single-nucleotide polymorphisms of MMP-2, -8, -9 and TIMP-1
were not associated with tumour-related survival. Only the gene promoter MMP-2 1306C4T polymorphism correlated significantly
with the protein level within the tumours. First-order dendrogram cluster analysis combined with Cox analysis identified the
MMP-7 181A4G and TIMP-2303C4T polymorphism combination to have a major impact on patients survival outcome. We conclude
that MMP-related SNPs, especially MMP-7 181A4G and TIMP-2303C4T, may be helpful in identifying gastric cancer patients with
a poor clinical outcome.
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In the process of tumour dissemination and metastasis, matrix
metalloproteinases (MMPs) and their tissue inhibitors (TIMPs)
play an important role in the invasion of tissue, vascular and
lymphatic basal membranes and the subsequent coordinated
proteolytic breakdown and reconstitution of extracellular matrix
(Kohn and Liotta, 1995). Matrix metalloproteinases also modulate
cell proliferation, apoptosis and host immune surveillance (Egeblad
and Werb, 2002). Immunohistochemical and in situ hybridisation
studies as well as quantitative assays have demonstrated that gastric
carcinomas contain enhanced amounts of MMPs (Nomura et al,
1995; Honda et al, 1996; Mori et al, 1997). We previously reported
significantly enhanced MMP and TIMP levels in gastric carcinomas,
but only MMP-2 was independently associated with a poor overall
survival of the patients (Kubben et al, 2006). Single-nucleotide
polymorphisms (SNPs) within MMP genes are thought to influence
the expression of MMPs and/or even seem to be associated with the
susceptibility for the development of malignancy. For instance, a
functional SNP in the MMP-2 gene promoter ( 1306C4T) was
found to be associated with the risk of the development, but not the
metastatic behaviour of gastric cardia adenocarcinoma, in an ethnic
Chinese population (Miao et al, 2003). Furthermore, the frequency
of a functional SNP of MMP-7 ( 181A4G) was found to be
significantly higher in gastric cardiac carcinoma patients compared
to controls in another Chinese study (Zhang et al, 2005).
Particularly, genotypes with the MMP-7 181G allele (A/GþG/G)
showed a significantly increased susceptibility for gastric cardiac
carcinoma with an odds ratio of 1.96 (Zhang et al, 2005). Finally, a
significant association in Japanese gastric cancer patients was
found between an SNP in the promoter of the MMP-9 gene
( 1562C4T) and the degree of tumour invasion, clinical stage and
lymphatic invasion (Matsumura et al, 2005). However, as indicated
above, these studies on MMP-SNPs in gastric carcinoma patients
describe ethnic Chinese and Japanese populations with a known
high incidence of gastric cancer.
In the present study, we determined the genotype distribution
and allele frequencies of SNPs of MMP-2, -7, -8 and -9, and of
TIMP-1 and -2 in a cohort of 79 Caucasian gastric carcinoma
patients, in which we previously assessed clinical relevance of the
respective protein levels. In order to get insight into the functional
and clinical contribution of these MMP-related gene polymorph-
isms, we assessed the relation between the distribution of these
SNPs and the respective protein levels in tumour and adjacent
normal tissue as well as the relation of the SNPs with established
clinico-pathological parameters and the relation of the gene
polymorphisms with tumour-related survival.
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Patients and study design
Fresh histologically normal tissue specimens of 79 patients (21
females and 58 males, mean age 66 years, range 35–91 years) who
underwent resection for primary gastric adenocarcinoma at the
department of Oncologic Surgery of the Leiden University Medical
Center were collected prospectively, as described before (Janssen
et al, 2002). Various clinico-pathological data were (re-)evaluated
or collected from patient files by one gastroenterologist and one
pathologist (Janssen et al, 2002). All carcinomas were classified
according to the TNM classification (Hermanek and Sobin, 1992)
and localisation as well as diameters of the tumours were
registered. Microscopical histological parameters, including differ-
entiation-grade, classification according to WHO, Borrmann and
Laure ´n, as well as the presence of Helicobacter pylori (Hp) and
intestinal metaplasia in the normal gastric mucosa were assessed.
All patients entered the study at operation date and a patient’s time
experience ended in the event of death or, when still alive, at the
common closing date. The minimal follow-up was 33 months with
a decreasing overall survival according to TNM stage, that is, from
TNM I (n¼23), to TNM II (n¼24), to TNM III (n¼25), and to
TNM IV (n¼7). Genomic DNA was isolated using the salting out
method (Miller et al, 1988). In addition, DNA was extracted from
peripheral blood leucocytes of 169 healthy volunteers (38% male,
median age 33 years (range 18–73 years), 495% Caucasian) as
described before (van der Veek et al, 2005).
Single-nucleotide polymorphism analyses
Genotypes were analysed by PCR-based techniques as described in
Table 1.
Antigen determination and protein concentration
From 50–100mg of wet tissue samples, homogenates were
prepared. The samples were wet weighted, and 1ml of 0.1M
Tris-HCl (pH 7.5) with 0.1% (v.v
 1) Tween-80 extraction buffer
per 60mg sample was added as described previously. The protein
concentration was determined using the method of Lowry et al
(1951). Specific ELISAs for the MMP and TIMP antigen
determination were performed as recently described (Kubben
et al, 2006).
Statistical analysis
Statistical analyses were performed using SPSS11.0 Statistical
Package (2004, SPSS Inc., Chicago, IL, USA). Hardy–Weinberg
analysis was performed using the chi-square (w
2) or Fisher’s
exact test to examine differences in the distribution of alleles and
genotypes between patients and controls. Odds ratios and
confidence intervals (95%) were calculated by logistic regression.
For the tumour-related survival analysis, the clinico-patho-
logical parameters were dichotomised as described before
(Sier et al, 1996). Univariate survival analyses were performed
with the Cox proportional hazards model, using the clinico-
pathological parameters and MMP-SNPs, resulting in the
identification of covariates that significantly correlated with the
survival of the patients. Multivariate survival analysis was
performed by separately adding the MMP-SNPs variables to all
the dichotomised clinico-pathological parameters. Tumour-
related survival curves were constructed using the method of
Kaplan and Meier including the log rank test. Group means
for antigen levels were compared using two-tailed Mann–
Whitney U-tests. Differences were considered significant when
Pp0.05.
Table 1 Primer sequences and PCR conditions for amplification of MMP and TIMP SNPs
SNP Method Primer Sequence Location Annealing BP Enzyme Reference
MMP-2 1575G4A RFLP-PCR Outer primers ACCAGACAAGCCTGAACTTGTCTGA Promoter 631C, 35 cycles 542 BspHI (Harendza et al, 2003)
TGTGACAACCGTCTCTGAGGAATG
MMP-2 1306C4T Tetra-primer
ARMS-PCR
Outer forward ACCAGACAAGCCTGAACTTGTCTGA Promoter 631C, 35 cycles 542 (Ye et al, 2001)
Outer reverse TGTGACAACCGTCTCTGAGGAATG 3792
Inner forward ATATTCCCCACCCAGCACGCT 11
Inner reverse GCTGAGACCTGAAGAGCTAAAGAGTTG
MMP-7 181A4G RFLP-PCR Forward TGGTACCATAATGTCCTGAATG Promoter 551C, 35 cycles 150 EcoRI (Jormsjo ¨ et al, 2001)
Reverse
mismatch
TCGTTATTGGCAGGAAGCACACAATGAATT
MMP-7 153C4G RFLP-PCR Forward
mismatch
ACGAATACATTGTGTGCTTCCTGCCAATCA Promoter 551C, 30 cycles 158 NlaIII (Jormsjo ¨ et al, 2001)
Reverse TTTATATAGCTTCTCAGCCTCG
MMP-8 799C4T RFLP-PCR Forward CTGTTGAAGGCCTAGAGCTGCTGCTCC Promoter 581C, 35 cycles 968 SfcI (Wang et al, 2004)
Reverse CATCTTCTCTTCAAACTCTACCC
MMP-8+17C4G RFLP-PCR Forward CTGTTGAAGGCCTAGAGCTGCTGCTCC Transcription
start
581C, 35 cycles 668 DdeI (Wang et al, 2004)
Reverse CATCTTCTCTTCAAACTCTACCC
MMP-9 1562C4T RFLP-PCR Forward ATGGCTCATGCCCGTAATC Promoter 601C, 38 cycles 352 NlaIII
or SphI
(Zhang et al, 1999)
Reverse TCACCTTCTTCAAAGCCCTATT
TIMP-1372C4T RFLP-PCR Forward GCACATCACTACCTGCAGTC Exon 5
phe 124 phe
541C, 35 cycles 175 BssSI (Wollmer et al, 2002)
Reverse GAAACAAGCCCACGATTTAG
TIMP-2 418G4C RFLP-PCR Forward CGTCTCTTGTTGGCTGGTCA Promotor 641C, 35 cycles 304 BsoBI (Zhou et al, 2004)
Reverse CCTTCAGCTCGACTCTGGAG
TIMP-2303C4T RFLP-PCR Forward TAGGAACAGCCCCACTTCTG Exon 3
ser 101 ser
601C, 35 cycles 119 TspRI (Krex et al, 2003)
Reverse CCTCCTCGGCAGTGTGTG
ARMS¼amplification refractory mutation system; MMP¼matrix metalloproteinase; PCR¼polymerase chain reaction; RFLP¼restriction fragment length polymorphism;
SNP¼single-nucleotide polymorphism; TIMP¼tissue inhibitor of metalloproteinase. Deliberate mismatches in primers are underlined.
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The genotype distribution and allele frequencies of the SNPs for
MMP-2, -7, -8, -9, TIMP-1 and -2 for the 79 gastric cancer patients
and 169 control subjects are summarised in Table 2. Single-
nucleotide polymorphisms  1306C4T and  1575G4A for
MMP-2 were found to be in complete linkage disequilibrium and
consequently, in the rest of the study only MMP-2 1306C4T will be
described. None of the genotype distributions in the control group
or in the cancer patients deviated from the Hardy–Weinberg
equilibrium (data not shown). Matrix metalloproteinase-7 181A4G
was the only polymorphism differently distributed among gastric
carcinoma patients compared with control subjects: AA 43.0%, AG
46.8%, and GG 10.1% in patients vs AA 27.2%, AG 62.7% and GG
10.1% in controls (Po0.04; Table 2). Comparison of the genotype
distribution of our Caucasian control subjects with those
published on other mainly Asiatic control groups (Wollmer et al,
2002; Ghilardi et al, 2003; Krex et al, 2003; Miao et al, 2003; Wang
et al, 2004; Zhou et al, 2004; Matsumura et al, 2005; Zhang et al,
2005) showed significant differences for MMP-2 1306C4T, MMP-
7 181A4G, TIMP-1372C4T and TIMP-2 418G4C (Table 3).
All the SNPs were evaluated for association with the clinico-
pathological parameters. Correlations were found for MMP-
2 1306C4T with Borrmann’s classification (fungating vs infiltrating:
Table 2 Allele frequencies and genotype distribution of MMP and TIMP SNPs in gastric carcinoma patients (n¼79) and controls (n¼169)
Patients Controls
SNP n % n % n % n % n % n % v
2 P OR CI
MMP-2 1306C4T Allele C 124 78.5 T 34 21.5 C 257 76.0 T 81 24.0 0.362 NS
Genotype CC* 50 63.3 CT 24 30.4 TT 5 6.3 CC 102 60.4 CT 53 31.4 TT 14 8.3 0.361 NS 0.833 0.51–1.53
MMP-7 181A4G Allele A 105 66.5 G 53 33.5 A 198 58.6 G 140 41.4 2.810 NS
Genotype AA* 34 43.0 AG 37 46.8 GG 8 10.1 AA 46 27.2 AG 106 62.7 GG 17 10.1 6.533 o0.04 0.495 0.28–0.87
MMP-7 153C4T Allele C 149 94.3 T 9 5.7 C 320 94.7 T 18 5.3 0.029 NS
Genotype CC* 70 88.6 CT 9 11.4 TT — 0 CC 151 89.3 CT 18 10.7 TT — 0 0.031 NS 1.079 0.46–2.52
MMP-8 799C4T Allele C 84 53.2 T 74 46.8 C 191 56.5 T 147 43.5 0.487 NS
Genotype CC* 19 24.1 CT 46 58.2 TT 14 17.7 CC 55 32.5 CT 81 48.0 TT 33 19.5 2.509 NS 1.524 0.83–2.80
MMP-8+17C4G Allele C 147 93.0 G 11 7.0 C 309 91.4 G 29 8.6 0.380 NS
Genotype CC* 68 86.1 CG 11 13.9 GG — 0 CC 141 83.4 CG 27 16.0 GG 1 0.6 0.660 NS 0.781 0.37–1.66
MMP-9 1562C4T Allele C 137 86.7 T 21 13.3 C 286 84.6 T 52 15.4 0.376 NS
Genotype CC* 59 74.7 CT 19 24.0 TT 1 1.3 CC 120 71.0 CT 46 27.2 TT 3 1.8 0.394 NS 0.830 0.45–1.52
TIMP-1372C4T Allele C 74 46.8 T 84 53.2 C 167 49.4 T 171 50.6 0.285 NS
Genotype~ CC* 5 23.8 CT 10 47.6 TT 6 28.6 CC 24 22.4 CT 59 55.2 TT 24 22.4 0.481 NS 0.925 0.31–2.79
# C* 27 46.6 T 31 53.4 C 30 48.4 T 32 51.6 0.040 NS 1.076 0.53–2.21
TIMP-2303C4T Allele C 146 92.4 T 12 7.6 C 301 89.0 T 37 11.0 1.359 NS
Genotype CC* 68 86.1 CT 10 12.7 TT 1 1.3 CC 133 78.7 CT 35 20.7 TT 1 0.6 2.588 NS 0.598 0.29–1.25
TIMP-2 418G4C Allele G 157 99.4 C 1 0.6 G 337 99.7 C 1 0.3 0.305 NS
Genotype GG* 78 98.7 GC 1 1.3 CC — 0 GG 168 99.4 GC 1 0.6 CC — 0 0.306 NS 2.154 0.13–34.9
CI¼confidence interval; MMP¼matrix metalloproteinase; NS¼not significant; OR¼odds ratio; PCR¼polymerase chain reaction; SNP¼single-nucleotide polymorphism;
TIMP¼tissue inhibitor of metalloproteinase. The w
2 test was used to examine differences in the distributions of alleles and genotypes between patients and controls. OR and
95% CI were calculated by logistic regression using marked genotypes (*) as reference groups.
Table 3 Comparison of genotype distributions of the control subjects from this study (n¼169, 107~/62#) with the control groups from previously
published studies
MMP-2
 1306C4T
MMP-7
 181A4G
MMP-7
 153C4T
MMP-8
 799C4T
MMP-8
+17C4G
MMP-9
 1562C4T
TIMP-1
372C4T
TIMP-2
303C4T
TIMP-2
 418G4C
Lin et al, 2004 Ghilardi
et al, 2003
Ghilardi
et al, 2003
Wang
et al, 2004
Wang
et al, 2004
Demacq
et al, 2006
Krex et al, 2003 Krex et al, 2003 Hirano et al, 2001
n¼147 (A) n¼111 (C) n¼111 (C) n¼216 (B) n¼216 (B) n¼200 (#C) n¼24~/20# (C) n¼41 (C) n¼40 (A)
w
2 6.0 w
2 1.7 w
2 1.7 w
2 3.8* w
2 0.1* w
2 5.8 ~w
2 4.1, #w
2 5.0 w
2 0.3 w
2 66.6
NS NS NS NS NS NS NS, Pp0.025 NS Pp0.001
Miao et al, 2003 Zhang et al, 2005 Lose et al, 2005 Lose et al, 2005 Wang et al, 1999 Zhou et al, 2004
n¼789 (A) n¼350 (A) n¼392 (C) n¼34~/33# (C) n¼82 (C) n¼509 (A)
w
2 16.7 w
2 217.2 w
2 0.7 ~w
2 8.2, #w
2 1.3 w
2 3.7* w
2 66.7
Pp0.001 Pp0.001 NS NS, NS NS Pp0.001
(Xu et al, 2004) Matsumura et al, 2005 Wollmer et al, 2002
n¼126 (A) n¼224 (A) n¼159~/114# (C)
w
2 8.6 w
2 0.2 ~w
2 8.0, #w
2 0.0
Pp0.025 NS Pp0.025, NS
Zhou et al, 2004
n¼509 (A)
w
2 23.1
Pp0.001
MMP¼matrix metalloproteinase; NS¼not significant; TIMP¼tissue inhibitor of metalloproteinase. *Allele distribution. (A): Asiatic population, (B): Afro-American population,
(C): Caucasian population.
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2 3.5,
P¼0.06), MMP-7 181A4G with the presence of Hp (negative vs
positive: AA 60% and AG/GG 40% vs AA 21% and AG/GG 79%; w
2
7.8, P¼0.005) and TIMP-2303C4T with the WHO classification
(differentiated vs not differentiated: CC 93% and CT/TT 7% vs CC
72 and CT/TT 28%; w
2 5.9, P¼0.03).
The prognostic value for tumour-related survival of the
respective SNPs was analysed using Cox proportional hazards
analyses (Table 4). In the univariate analyses, TIMP-2303C4T was
significantly correlated with survival (Figure 1A), whereas MMP-
7 181A4G showed a trend (Figure 1B). From the clinico-
pathological parameters, only TNM classification and the presence
of intestinal metaplasia were significantly associated with survival,
whereas the localisation showed a trend. In a multivariate analysis
against all the clinical parameters TIMP-2303C4T kept its
significance, indicating its potential value as an independent
prognostic marker. A dendrogram showing a two-dimensional
unsupervised hierarchical cluster analysis for all 79 patients using
all the SNPs determined in this study is presented in Figure 2.
Interestingly, the first-order cluster (I) separated the eight patients
with mutations in both the survival-associated SNPs, that is,
MMP-7 181A4G and TIMP-2303C4T, from the rest of the patients.
Further analyses of this SNP combination revealed a stepwise and
statistically significant poorer tumour-related survival for these
mutations (0% (0 out of 11 patients) vs 32% (12 out of 37 patients)
vs 52% (16 out of 31 patients); w
2 9.7, Pp0.01). Cox analyses
Table 4 Univariate and multivariate Cox proportional hazard analysis for gastric cancer patients testing SNPs for MMP and TIMP vs clinico-pathological
parameters
Univariate Multivariate
Parameter n HR CI 95% P HR CI 95% P
Gender F vs M 21–58 0.706 0.390–1.278 NS 0.606 0.322–1.138 NS
Age omedian4 40–39 1.231 0.709–2.138 NS 1.422 0.749–2.701 NS
TNM 1 23 1 — — 1 — —
vs 2 24 3.041 1.302–7.102 0.01 4.282 1.629–11.257 0.003
vs 3 25 2.995 1.293–6.933 0.01 3.119 1.175– 8.280 0.022
vs 4 7 7.175 2.420–21.271 0.0005 19.661 5.096–75.855 0.0005
Laure ´n diffuse/mix vs intestinal 28–50 0.913 0.522–1.595 NS 1.281 0.344–4.774 NS
WHO differentiated vs undiff. 53–25 1.152 0.652–2.033 NS 1.846 0.470–7.251 NS
Borrmann fungating vs infiltrating 54–23 1.077 0.576–2.013 NS 0.677 0.338–1.356 NS
Localisation Rest vs cardia 45–34 1.715 0.980–3.001 0.059 2.878 1.410–5.874 0.004
Diameter p5 vs 45cm 45–34 1.07 0.615–1.861 NS 0.612 0.324–1.158 NS
Intestinal metaplasia Not vs present 37–42 0.499 0.283–0.880 0.016 0.704 0.378–1.312 NS
SNP
MMP-2 1306C4T CC vs CT/TT 50–29 0.756 0.421–1.358 NS 1.158 0.578–2.321 NS
MMP-7 181A4G AA vs AG/GG 34–45 1.718 0.965–3.057 0.066 1.637 0.850–3.152 NS
MMP-7 153C4T CC vs CT 70–9 1.096 0.467–2.575 NS 1.137 0.396–3.269 NS
MMP-8 799C4T CC vs CT/TT 19–60 0.681 0.376–1.234 NS 0.607 0.302–1.222 NS
MMP-8+17C4G CC vs CG 68–11 1.349 0.656–2.775 NS 1.364 0.516–3.606 NS
MMP-9 1562C4T CC vs CT/TT 59–20 1.127 0.598–2.126 NS 1.006 0.482–2.101 NS
TIMP-1372C4T CC vs CT/TT 32–47 1.125 0.644–1.967 NS 0.739 0.387–1.411 NS
TIMP-2303C4T CC vs CT/TT 68–11 3.224 1.571–6.616 0.001 4.445 1.808–10.928 0.001
TIMP-2 418G4C GG vs GC 78–1 ND ND ND ND ND ND
MMP-7 181A4G and AA-CC 31 1 — — 1 — —
TIMP-2303C4T vs AG/GG-CC 37 1.896 1.011–3.558 0.046 1.911 0.947–3.856 0.071
vs AA or AG/GG-CT/TT 11 3.859 1.578–9.442 0.003 5.323 1.736–16322 0.003
CI¼confidence interval; F¼female; HR¼hazard ratio; M¼male; MMP¼matrix metalloproteinase; ND¼not defined; NS¼not significant; SNP¼single-nucleotide
polymorphism; TIMP¼tissue inhibitor of metalloproteinase; TNM¼tumour node metastasis; WHO¼World Health Organisation.
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Figure 1 Survival curves using tumour-related death for 79 gastric cancer patients subdivided by the presence of a SNP in (A) the TIMP-2 gene
(303C4T) and (B) the MMP-7 gene ( 181A4G).
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TIMP-2303C4T combination, as indicated in Table 4 and illustrated
in Figure 3.
The relation between the genotype distribution of the SNPs and
the protein levels in normal and tumour tissue is shown in Table 5.
As expected, the exon-located SNPs were not found to be
accompanied by changes in the respective protein levels. The
promoter-located SNPs showed some trends with the protein
levels, but the only relevant significant difference was found for
MMP-2 1306C4T within tumour tissue.
DISCUSSION
Because some gene polymorphisms of MMPs and TIMPs have been
found to be related to disease susceptibility and changed gene
transcription in vitro, we investigated whether gastric cancer is
associated with SNPs of MMP-2, -7, -8 and -9, or their inhibitors
TIMP-1 and TIMP-2. The only SNP that was distributed
significantly differently among gastric carcinoma patients com-
pared to our control population was MMP-7 181A4G, with more
patients of the AA genotype than in controls. The latter was
not expected from previous studies on gastrointestinal cancer
(Ghilardi et al, 2003; Zhang et al, 2005) and is most likely caused
by ethnic differences (Asiatic vs Caucasian; Table 3), disease
localisation (gastric vs colon) and the relatively low number of
patients included in the studies. In our study, the gastric cancer
patients with the variant AG/GG genotype showed worse survival
data than the AA patients (Table 4 and Figure 1B), although the
difference did not fully reach statistical significance. The fact that
tumours of the AG/GG patients did not contain higher MMP-7
antigen levels in our study suggests that the presence of SNP MMP-
7 181A4G alone is not directly translated into an enhanced tumour
Figure 2 Dendrogram of a two-dimensional unsupervised hierarchical
cluster analysis for 79 gastric cancer patients using SNPs of MMP-
2 1306C4T, MMP-7 181A4C (A),  153C4G (B), MMP-8 799C4T(C),
þ17C4G(D), MMP-9 1562C4T, TIMP-1372C4T, and TIMP-2303C4T(E),
 418G4C(F). For all the SNPs, 0 stands for the reference genotype and 1
for the combined other genotypes as described in Table 2. Because of the
distribution, for MMP-8 799C4T(C) a three-group subdivision was used:
0¼CC, 1¼CT, 2¼TT. Status: 0¼alive or not tumour-related death,
1¼tumour-related death.
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Figure 3 Survival curves using tumour-related death for 79 gastric
cancer patients subdivided by the presence of combined polymorphisms in
the MMP-7 gene ( 181A4G) and TIMP-2 gene (303C4T).
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previously shown localised presence of MMP-7 at the invasive
front of tumours, immunohistochemical or in vitro studies might
further elucidate this functional relationship. The other striking
correlation of MMP-7 181A4G in this study is with the presence
of Hp. Gastric cancer patients with the AG/GG genotype were
significantly more often Hp-positive, which might indicate an
enhanced susceptibility for this bacterium. The presence of Hp is
associated with the development of gastric cancer and stimulation
of MMP-7 production by Hp in human gastric epithelial cells has
previously been suggested as a possible mechanism predisposing
towards gastric neoplasia (Wroblewski et al, 2003; Chen et al,
2004).
Tissue inhibitor of metalloproteinase-2 is involved in the
regulation of MMP-2 activity (Howard et al, 1991; Wang et al,
2000). In addition, TIMP-2 has been shown to promote cell growth
(Hayakawa et al, 1994). Enhanced amounts of TIMP-2 protein are
found to be associated with prostate cancer malignancies (Ross
et al, 2003), but for colon and gastric cancer the correlation with
clinico-pathological parameters has not been established (Ring
et al, 1997; Joo et al, 2000). In our study, the CT/TT variant of
TIMP-2303C4T was observed more frequently in undifferentiated
gastric carcinomas (WHO classification) and it was associated with
worse tumour-related survival of gastric cancer patients. Tissue
inhibitor of metalloproteinase-2303C4T is located in exon 3 with no
effect on the final amino-acid sequence of the protein (S101S) and
no effect on the total TIMP-2 expression between gastric normal
and tumour tissue (Table 5). Therefore, the TIMP-2303C4T SNP
behaves as a disease susceptibility gene polymorphism by a so far
undefined mechanism. The other SNP for TIMP-2 in this study
( 418G4C), localised in the promoter of the gene, has been
described to abolish the Sp1-binding site and therefore may
downregulate TIMP-2 gene expression (Hirano et al, 2001). A
previous study reported that the variant TIMP-2 418G4C genotype
(GC or CC) was indeed associated with a moderately reduced risk
of breast cancer in a Chinese population (Zhou et al, 2004).
Because our group of Caucasian gastric cancer patients contained
only one patient with the variant genotype (GC), we could not
determine an association with tumour staging, patient survival or
antigen expression.
The first-order cluster in a two-dimensional unsupervised
hierarchical cluster analysis including all SNPs clearly separated
the patients with mutations in both the survival-associated SNPs,
that is, MMP-7 181A4G and TIMP-2303C4T from the rest of the
patients. Cox analysis confirmed this SNP combination as a
prognostic parameter for gastric cancer. Although results of cluster
analysis of SNPs in gastric cancer have not been published before,
hierarchical cluster analysis of patterns of chromosomal aberra-
tions in gastric cancer patients identified patients with worse
prognosis as well (Weiss et al, 2003), confirming the validity of
such an approach.
The ( 1306C4T) SNP in the promoter of the MMP-2 gene has
also been found to diminish promoter activity by abolishing the
Sp1-binding site (Price et al, 2001). Consequently, the variant
genotypes (CT/TT) are expected to produce less MMP-2 antigen,
which consequently might be associated with decreased cancer risk
or better survival of the patients (Sier et al, 1996). Although we did
not find a significant difference in distribution of MMP-2 1306C4T
between gastric cancer patients and controls, the tumours from
patients with the CT/TT genotypes contained significantly less
MMP-2 antigen than the CC genotype (Table 5). This relation was
expected, but as far as we know, never shown before. The fact that
the MMP-2 1306C4T status on its own was not correlated with
survival might be explained by the complicated activation
mechanism of MMP-2 in which several other proteins are involved.
Changes in MMP-2 antigen levels are therefore not directly
correlated with MMP-2 activity levels. The fact that we did not
find a relation with survival in our group of patients supports
the study of Miao et al (2003), describing that the CC genotype was
not associated with higher risk of metastasis at the time
of diagnosis. A weak but significant difference in genotype
distribution of MMP-2 1306C4T and gastric carcinomas, classified
according to the Borrmann classification, was observed with
the highest percentage of the CC genotype in type 1/2 (fungating)
preceding infiltrating tumours (type 3/4). This underscores
the role of MMP-2 in breaking down the extracellular matrix
in early gastric cancer which has been suggested before (Miao
et al, 2003).
The genotype distribution of MMP-9 1562C4T in our group of
healthy controls was not different from other publications. We did
not find differences in genotype distribution for MMP-9 1562C4T
between gastric cancer patients and controls either, which is in
agreement with the study of Matsumura et al (2005) in Japanese
patients. However, that study showed significant associations of
the CT/TT genotype with depth of invasion, lymphatic invasion
and TNM classification. In our study, MMP-9 1562C4T was not
correlated with clinico-pathological parameters or survival. More-
over, MMP-9 antigen levels in normal as well as tumour tissue of
gastric cancer patients with the MMP-9 1562C4T genotype were not
enhanced, as was recently also found in plasma of healthy subjects
(Demacq et al, 2006). Our results indicate that the presence of the
T allele variant in the MMP-9 promoter ( 1562C4T) is not
associated with clinical outcome in our Caucasian group of gastric
cancer patients.
Neutrophils secrete both gelatinase B (MMP-9) and neutrophil
collagenase (MMP-8) after stimulation. Matrix metalloproteinase-8
Table 5 Association between the presence of SNPs and the protein levels (mean7s.e.m. in ngmg
 1 protein) within tissue of MMPs and TIMPs in 79
gastric carcinoma patients
SNP
Protein level
Located in promoter Normal mucosa P-value Tumour P-value
MMP-2 1306C4T CC vs CT/TT 5.070.5 4.570.7 NS 18.272.4 14.973.8 0.03
MMP-7 153C4T CC vs CT
a 2.270.6 0.770.0 0.019 47.1714.1 46.1716.4 NS
MMP-7 181A4G AA vs AG/GG 1.370.4 2.170.6 NS 52.1722.3 43.4715.0 NS
MMP-8 799C4T CC vs CT/TT 139731 83712 0.044 305767 326760 NS
MMP-8+17C4G CC vs CG 98719 95715 NS 302751 4407140 NS
MMP-9 1562C4T CC vs CT/TT 9.771.1 7.071.5 NS 26.972.8 19.473.3 NS
TIMP-2 418G4C GG vs GC
b 6.070.3 5.1 NS 6.370.4 5.2 NS
Located in exon
TIMP-1372C4T CC vs CT/TT 8.771.6 7.770.7 NS 18.872.6 15.771.4 NS
TIMP-2303C4T CC vs CT/TT 6.070.3 5.670.6 NS 6.070.4 7.571.6 NS
MMP¼matrix metalloproteinase; NS¼not significant; SNP¼single-nucleotide polymorphism; TIMP¼tissue inhibitor of metalloproteinase.
an¼3.
bn¼1.
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in ovarian cancer (Stadlmann et al, 2003). Levels of MMP-8 and -9
correlated significantly with each other and with TIMP-1 levels,
but were not related to tumour size or prognosis in human breast
cancer (Duffy et al, 1995). Nothing has been published thus far
about SNPs for MMP-8 and cancer, but three MMP-8 promoter
haplotypes (MMP-8–799C4T, MMP-8þ17C4G and MMP-8 381A4G)
have been found to be associated with preterm rupture of
membranes in delivery, indicating a functional role on MMP-8
expression (Wang et al, 2004). Because MMP-8þ17C4G and MMP-
8 381A4G were found to be in complete linkage disequilibrium, we
decided to study the distribution of MMP-8–799C4T, MMP-
8þ17C4G in our group of gastric cancer patients. However,
we did not find any relation of both SNPs with protein levels,
clinico-pathological parameters, or survival in this study.
TIMP-1 is a ubiquitous glycoprotein capable of inhibiting all
activated collagenases (Gomez et al, 1997). Tissue inhibitor of
metalloproteinases were previously found not to be correlated with
tumour stage, histological type, lymph node status or survival in
human gastric cancer (Murray et al, 1998). We did not find any
relation of TIMP-1372C4T with gastric carcinoma, protein level or
survival of the patients.
Taken together, our data indicate that MMP and TIMP gene
polymorphisms contribute to gastric carcinogenesis. Determina-
tion of these gene polymorphisms, especially MMP-7 181A4G and
TIMP-2303C4T both as single parameter and in combination as a
cluster, might be helpful to identify gastric cancer patients with a
poor clinical outcome and in need of (neo)-adjuvant treatment
aiming at better outcome.
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